SBIR-STTR Award

Endothelial Progenitor Cells for Assessing Toxicological Response Variability in Humans
Award last edited on: 1/12/18

Sponsored Program
SBIR
Awarding Agency
NIH : NIEHS
Total Award Amount
$1,748,997
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
John William Ludlow

Company Information

Britebio Inc

3200 East HWY 54 Suite 100
Research Triangle Park, NC 27709
   (919) 547-0692
   information@britebio.com
   www.britebio.com
Location: Single
Congr. District: 04
County: Durham

Phase I

Contract Number: 1R43ES023527-01
Start Date: 9/15/13    Completed: 8/31/14
Phase I year
2013
Phase I Amount
$248,998
Currently, toxicological risk assessment lacks direct estimation of the magnitude and variability of human responses to environmental toxicants. Specifically, there is very little data on the effects of low dose toxicants on human developmental processes, including cellular differentiation. That is because the current basis of toxicological assessment, animals and immortalized cell lines, cannot adequately model the impact of low level toxicant exposure on human population. A potential alternative detection platform should enable incorporation of human variability in screening of a large number of toxicants in a high-throughput manner. To establish such a platform, we suggest using human donor- specific cells that can be (a) isolated in a non-invasive manner, (b) easily expanded in culture, and (c) cryopreserved without loss of viability. We propose that human endothelial progenitor cells or endothelial colony forming cells (ECFCs), a population of CD31+/CD34+ pluripotent cells found in circulation, would fulfill these requirements. In vitro, ECFCs are highly proliferative and can differentiate into mature endothelial cells (ECs). The overall goal of this research is to evaluate the effect of chemical toxicants on viability, proliferation, and differentiation of ECFCs derived from different individuals. Specifically in this proposal, we will determine the feasibility of ECFCs as a platform for high-throughput chemical toxicity testing. For this purpose, we selected three known environmental toxicants found at low levels in neonatal and adult peripheral blood: bisphenol A (BPA), perfluorooctanoic acid (PFOA), and cadmium. The proposed study is the key step in the development of a novel, robust, and comprehensive platform utilizing donor-specific pluripotent cells. At the conclusion of this project, we will demonstrate the amenability of ECFC-based assays for high- throughput evaluation of environmental toxicants. ECFC-based toxicological assays can become an invaluable tool for functional assessment of human genetic diversity and identification of population subgroups most vulnerable to chemical hazards.

Public Health Relevance Statement:


Public Health Relevance:
In this study, we propose to test a novel, robust, and comprehensive platform for toxicological risk assessment utilizing donor-specific pluripotent cells. Such platform would be an invaluable tool for the functional analysis of human genetic diversity and identification of population subgroups most vulnerable to toxicants.

NIH Spending Category:
Biotechnology; Stem Cell Research

Project Terms:
Acids; Adult; Affect; Animals; base; Biological Assay; Biology; bisphenol A; Blood Circulation; Blood Vessels; Blood Volume; Cadmium; CD34 gene; Cell Count; Cell Culture Techniques; Cell Differentiation process; cell growth; Cell Line; Cell Proliferation; Cell Survival; Cells; Cellular biology; Chemicals; Collaborations; Cost Effectiveness Analysis; Cryopreservation; Culture Media; Data; Detection; Development; Developmental Process; Dose; electric impedance; Endothelial Cells; Ensure; Evaluation; Future; Goals; hazard; high throughput screening; Human; Human Genetics; immortalized cell; In Vitro; Individual; instrumentation; Ionizing radiation; Legal patent; Luciferases; Measurement; Mediating; Modeling; Neonatal; NF-kappa B; Nitric Oxide; North Carolina; novel; Outcome; PECAM1 gene; peripheral blood; Population; Population Sciences; Production; Property; public health relevance; Reporter; Reproducibility; Research; Research Personnel; research study; response; Right-On; Risk Assessment; Scientist; screening; Signal Pathway; Signal Transduction Pathway; Stem cells; Subfamily lentivirinae; Subgroup; Testing; Time; tool; Toxic Environmental Substances; toxicant; Toxicant exposure; Toxicity Tests; Toxicology; Universities; Variation (Genetics)

Phase II

Contract Number: 2R44ES023527-02
Start Date: 9/15/13    Completed: 8/31/17
Phase II year
2015
(last award dollars: 2016)
Phase II Amount
$1,499,999

Toxicological risk assessment lacks direct estimation of the magnitude and variability of human responses to environmental toxicants. Specifically, there is very little data on the effects of low dose toxicants on human developmental processes, including cellular differentiation. That is because the current basis of toxicological assessment, animals and immortalized cell lines, cannot adequately model the impact of low level toxicant exposure on human populations. An alternative detection platform should enable incorporation of human variability in screening of a large number of toxicants in a high-throughput manner. To establish such a platform, we propose using human donor-specific cells that can be (a) isolated in a non-invasive manner, (b) easily expanded in culture, and (c) cryopreserved without loss of viability. Our preliminary data suggest that human endothelial progenitor cells, or endothelial colony forming cells (ECFCs), a population of CD31+/CD34+ pluripotent cells found in circulating blood, would fulfill these requirements. ECFCs are highly proliferative in vitro and ca differentiate into mature endothelial cells (ECs). The overall goal of this research is to evaluate the effect of chemical toxicants on viability, proliferation, and differentiation of ECFCs derived from different individuals. Prior to our recent and successful completion of a Phase I program, we established cell culture parameters for ECFCs using a proprietary cell growth media supplement and completed initial toxicological risk assessment studies using low-dose ionizing radiation (LDIR). These studies confirmed the utility of ECFCs in toxicological risk assessment screening as well as their ability to broadly represent varying responses expected in human populations. Phase I studies successfully expanded these findings by performing ECFC toxicology assays using Bisphenol A (BPA), perfluorooctanoic acid (PFOA) and cadmium (Cd). ECFCs were found to be sensitive to BPA and Cd and less sensitive to PFOA, exhibiting donor-specific variability in proliferation rates. BPA and Cd also induced reactive oxygen species (ROS) production in a donor-specific manner. ECFCs were shown to experience oxidative stress and cell cycle arrest after exposure to toxicants. Elevated ROS production was shown to correlate with cell death after longer incubation times with toxicants. We found that the toxicants we analyzed also affected expression of endothelial-specific cell markers at a protein level in a newly developed differentiation assay. Phase II will focus on the continued development of this screening platform toward a validated quantitative high content imaging-based screen. Commercialization of the platform as a service will also be pursued as well as the production of kits for ECFC culture and subsequent toxicological analysis. Finally, the screen will be expanded to include toxicant-induced effects on ECFC differentiation into mature endothelial cells.

Public Health Relevance Statement:


Public Health Relevance:
Toxicological assays currently rely on a range of cell lines and in vivo models, as well as assays for viability and proliferation. Here, employing a primary human cell type (endothelial colony forming cells; ECFCs), Brite Bio and Creative Scientist have collaborated to develop a quantitative, high content imaging- based platform not only suited to environmental agent-induced cell death, but also differentiation disruption. Data derived from this screen is likely to be incorporated into toxicology forecasting algorithms, providing novel insights into differentiation disruption in a cell type critical to vascular development and maintenance.

NIH Spending Category:
Biotechnology; Stem Cell Research; Stem Cell Research - Nonembryonic - Human; Stem Cell Research - Umbilical Cord Blood/ Placenta; Stem Cell Research - Umbilical Cord Blood/ Placenta - Human

Project Terms:
Acids; Adult; Affect; Algorithms; Animal Model; Animals; Automation; base; Biological Assay; bisphenol A; Blood; Blood Circulation; Blood specimen; Blood Vessels; cadherin 5; Cadmium; CD34 gene; Cell Culture Techniques; Cell Cycle Arrest; Cell Death; Cell Differentiation process; cell growth; Cell Line; Cell Separation; Cell Survival; cell type; Cells; Chemicals; commercialization; Communities; Contracts; Culture Media; Data; Data Set; Detection; Development; Developmental Process; Differentiation Antigens; Donor Selection; Dose; electric impedance; Endothelial Cells; environmental agent; Environmental Health; Evaluation; Exhibits; experience; Exposure to; Flow Cytometry; Future; Glycocalyx; Goals; high throughput screening; Human; Image; imaging platform; immortalized cell; In Vitro; in vivo; in vivo Model; Individual; insight; Ionizing radiation; Link; Liquid substance; Maintenance; Mediating; Methods; Modeling; novel; Oxidative Stress; Pathway interactions; PECAM1 gene; peripheral blood; Phase; phase 1 study; Physiology; Population; Procedures; Production; programs; Proteins; public health relevance; Reactive Oxygen Species; Reagent; Reporting; repository; Research; response; Risk Assessment; Scientist; screening; Services; Signal Transduction; Source; Specific qualifier value; Stem cells; Time; Toxic effect; Toxic Environmental Substances; toxicant; Toxicant exposure; toxicant screening; Toxicology; Toxin; Translating; Umbilical cord structure; Validation; von Willebrand Factor; Western Blotting